Advertisement
Advertisement
MREO
Mereo BioPharma Group plc - ADR
0.42
USDSponsored
+0.04
+11.47%
Feb 06, 15:59 UTC -5
Closed
After-Market
0.42
0.00
+0.48%
MREO Earnings Reports
Positive Surprise Ratio
MREO beat 1 of 6 last estimates.
17%
Next Report
Date of Next Report
Mar 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.01
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Implied change from Q4 24 (Revenue/ EPS)
--
/-75.00%
Mereo BioPharma Group plc - ADR earnings per share and revenue
On Nov 10, 2025, MREO reported earnings of -0.01 USD per share (EPS) for Q3 25, beating the estimate of -0.02 USD, resulting in a 59.68% surprise. Revenue reached --, compared to an expected 11.90 million, with a -100.00% difference. The market reacted with a +5.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.01 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Mereo BioPharma Group plc - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Mereo BioPharma Group plc - ADR reported EPS of -$0.01, beating estimates by 59.68%, and revenue of $0.00, -100% below expectations.
How did the market react to Mereo BioPharma Group plc - ADR's Q3 2025 earnings?
The stock price moved up 5.65%, changed from $1.77 before the earnings release to $1.87 the day after.
When is Mereo BioPharma Group plc - ADR expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for Mereo BioPharma Group plc - ADR's next earnings report?
Based on 10
analysts, Mereo BioPharma Group plc - ADR is expected to report EPS of -$0.01 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement